Resiniferatoxin was not associated with sustained differences in the review outcomes reported but pain during instillation and withdrawal from treatment was significantly more common .
Groups treated with BCG tended to report less pain and fewer general symptoms .
Although adverse events were commonly reported , these were no more common after BCG than after placebo instillation .
The few data about Pentosanpolysulphate tended to favour the actively treated , but with wide confidence intervals ; there was little information about adverse events .
Oxybutinin instillation was associated with increased bladder capacity , reduced frequency , improved quality of life scores and fewer drop-outs .
Alkalinisation of urine pH did not make any clear difference , but with potentially wide confidence intervals .
BCG and oxybutin are reasonably well-tolerated and evidence is most promising for these .
Resiniferatoxin showed no evidence of effect for most outcomes and caused pain , which reduced treatment compliance .
There is little evidence for the other treatments included in this review .
BACKGROUND Painful Bladder Syndrome/Interstitial Cystitis ( PBS/IC ) occurs predominantly in women .
It is a poorly-understood condition with symptoms of bladder pain , urinary frequency , urgency and nocturia .
Treatments for PBS/IC include dietary/lifestyle interventions , oral medication , intravesical instillations and , in some cases , surgery .
Success rates are generally modest and there is little consensus as to the best form of treatment for this condition .
OBJECTIVES To assess the effectiveness of intravesical treatment for PBS/IC .
Psychometric analysis of the University of Wisconsin Interstitial Cystitis Scale: implications for use in randomized clinical trials.
PURPOSE A psychometric analysis of the University of Wisconsin Interstitial Cystitis Scale was conducted on 30 females previously enrolled in a phase II double-blind r and omized controlled trial evaluating the efficacy of six weekly intravesical instillations of TICE BCG .  The analyses were to : ( 1 ) evaluate the adequacy of the seven individual IC component items for measuring the range of patient responses ; ( 2 ) verify the 2-factor ( IC versus reference ) construct of the scale ; ( 3 ) evaluate the internal consistency and reliability of the IC items ; ( 4 ) better define the scale 's applicability and limitations ; and ( 5 ) if possible , make recommendations for improvements in the scale . MATERIAL S AND METHODS St and ard psychometric analyses were used to perform the evaluation , and included descriptive analysis of individual items , computing of item-total correlations and Cronbach 's internal consistency measures , and the application of factor and Rasch analyses . RESULTS The original 7-item IC scale was found to have ceiling effects that could limit its use in detecting small therapeutic differences . It was also found that the Pelvic item originally assigned to the reference set of items of the scale should be included as an IC item when used in a comparable IC population . After including this item into the IC scale Cronbach 's alpha was 0.84 , compared with 0.82 . CONCLUSIONS The UW-IC Scale has psychometric properties similar to other measurement instruments used in clinical research , and appears worthy of further study in well-characterized IC population s. The reference items suggest that IC patients do not indiscriminately report high values for generalized body complaints , but do so on bladder related symptoms as recorded by the IC items of the scale . Although the scale has limitations it appears applicable for use in future IC intervention clinical trials
Resiniferatoxin was not associated with sustained differences in the review outcomes reported but pain during instillation and withdrawal from treatment was significantly more common .
Groups treated with BCG tended to report less pain and fewer general symptoms .
Although adverse events were commonly reported , these were no more common after BCG than after placebo instillation .
The few data about Pentosanpolysulphate tended to favour the actively treated , but with wide confidence intervals ; there was little information about adverse events .
Oxybutinin instillation was associated with increased bladder capacity , reduced frequency , improved quality of life scores and fewer drop-outs .
Alkalinisation of urine pH did not make any clear difference , but with potentially wide confidence intervals .
BCG and oxybutin are reasonably well-tolerated and evidence is most promising for these .
Resiniferatoxin showed no evidence of effect for most outcomes and caused pain , which reduced treatment compliance .
There is little evidence for the other treatments included in this review .
BACKGROUND Painful Bladder Syndrome/Interstitial Cystitis ( PBS/IC ) occurs predominantly in women .
It is a poorly-understood condition with symptoms of bladder pain , urinary frequency , urgency and nocturia .
Treatments for PBS/IC include dietary/lifestyle interventions , oral medication , intravesical instillations and , in some cases , surgery .
Success rates are generally modest and there is little consensus as to the best form of treatment for this condition .
OBJECTIVES To assess the effectiveness of intravesical treatment for PBS/IC .